These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 32799584)

  • 1. Novel therapeutic agents for the treatment of diabetic kidney disease.
    Hartman RE; Rao PSS; Churchwell MD; Lewis SJ
    Expert Opin Investig Drugs; 2020 Nov; 29(11):1277-1293. PubMed ID: 32799584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New progress in drugs treatment of diabetic kidney disease.
    Wang J; Xiang H; Lu Y; Wu T; Ji G
    Biomed Pharmacother; 2021 Sep; 141():111918. PubMed ID: 34328095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential for improved outcomes in the prevention and therapy of diabetic kidney disease through 'stacking' of drugs from different classes.
    Bell DSH; Jerkins T
    Diabetes Obes Metab; 2024 Jun; 26(6):2046-2053. PubMed ID: 38516874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in the pharmacotherapeutic management of diabetic kidney disease.
    Block TJ; Batu D; Cooper ME
    Expert Opin Pharmacother; 2022 May; 23(7):791-803. PubMed ID: 35522659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.
    Zou H; Zhou B; Xu G
    Cardiovasc Diabetol; 2017 May; 16(1):65. PubMed ID: 28511711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium-Glucose Cotransporter-2 Inhibitors-Miracle Drugs for the Treatment of Chronic Kidney Disease Irrespective of the Diabetes Status: Lessons from the Dedicated Kidney Disease-Focused CREDENCE and DAPA-CKD Trials.
    Gohda T; Murakoshi M
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SGLT2 Inhibitors and the Diabetic Kidney.
    Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
    Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathophysiologic mechanisms in diabetic kidney disease: A focus on current and future therapeutic targets.
    Barrera-Chimal J; Jaisser F
    Diabetes Obes Metab; 2020 Apr; 22 Suppl 1():16-31. PubMed ID: 32267077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease.
    Kim DL; Lee SE; Kim NH
    Endocrinol Metab (Seoul); 2023 Feb; 38(1):43-55. PubMed ID: 36891650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Glucose-Lowering Agents for Diabetic Kidney Disease.
    de Vos LC; Hettige TS; Cooper ME
    Adv Chronic Kidney Dis; 2018 Mar; 25(2):149-157. PubMed ID: 29580579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mineralocorticoid Antagonism and Diabetic Kidney Disease.
    Lytvyn Y; Godoy LC; Scholtes RA; van Raalte DH; Cherney DZ
    Curr Diab Rep; 2019 Jan; 19(1):4. PubMed ID: 30673886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diabetic nephropathy: an insight into molecular mechanisms and emerging therapies.
    Warren AM; Knudsen ST; Cooper ME
    Expert Opin Ther Targets; 2019 Jul; 23(7):579-591. PubMed ID: 31154867
    [No Abstract]   [Full Text] [Related]  

  • 13. SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects.
    Garofalo C; Borrelli S; Liberti ME; Andreucci M; Conte G; Minutolo R; Provenzano M; De Nicola L
    Medicina (Kaunas); 2019 Jun; 55(6):. PubMed ID: 31212638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists.
    Winiarska A; Knysak M; Nabrdalik K; Gumprecht J; Stompór T
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advancements in diabetic kidney disease management: integrating innovative therapies and targeted drug development.
    Ghose S; Satariano M; Korada S; Cahill T; Shah R; Raina R
    Am J Physiol Endocrinol Metab; 2024 Jun; 326(6):E791-E806. PubMed ID: 38630049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury.
    Penno G; Garofolo M; Del Prato S
    Nutr Metab Cardiovasc Dis; 2016 May; 26(5):361-73. PubMed ID: 27105869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Narrative Review of Diabetic Kidney Disease: Previous and Current Evidence-Based Therapeutic Approaches.
    Mima A
    Adv Ther; 2022 Aug; 39(8):3488-3500. PubMed ID: 35751762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium-glucose cotransporter-2 inhibitors and non-steroidal mineralocorticoid receptor antagonists: Ushering in a new era of nephroprotection beyond renin-angiotensin system blockade.
    Shenoy SV; Nagaraju SP; Bhojaraja MV; Prabhu RA; Rangaswamy D; Rao IR
    Nephrology (Carlton); 2021 Nov; 26(11):858-871. PubMed ID: 34176194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease.
    Mima A
    J Diabetes Complications; 2018 Jul; 32(7):720-725. PubMed ID: 29880432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological management of youth with type 2 diabetes and diabetic kidney disease: a comprehensive review of current treatments and future directions.
    Tommerdahl KL; Kula AJ; Bjornstad P
    Expert Opin Pharmacother; 2023 Jun; 24(8):913-924. PubMed ID: 37071054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.